Hypoactive Sexual Desire Disorder
Conditions
Keywords
HSDD
Brief summary
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study. Subjects are randomly to one of seven treatment arms. The study investigates the effective dose of Lybrido in increasing the number of satisfactory sexual episodes in the domestic setting in 210 healthy female subjects with hypoactive sexual desire disorder and low sensitivity for sexual cues (30 subjects per group).
Interventions
DRUGPlacebo
Solid Oral Dosage. Maximum every other day (on an as needed basis)
DRUGSildenafil
Solid Oral Dosage. Maximum every other day (on an as needed basis)
DRUGTestosterone
Solid Oral Dosage. Maximum every other day (on an as needed basis)
Sponsors
Emotional Brain NY Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of written informed consent 2. Female 21 to 70 years of age, inclusive, pre- or postmenopausal, with HSDD (comorbidity with female sexual arousal disorder and/or female orgasmic disorder \[FOD; only as secondary diagnosis\] is allowed). The diagnosis of HSDD will be established by a trained professional. 3. Low sensitivity for sexual cues 4. Be involved in a stable relationship and have a partner who will be at home for the majority of the study duration 5. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant
Exclusion criteria
1. Any underlying cardiovascular condition, including unstable angina pectoris, that would preclude sexual activity 2. History of myocardial infarction, stroke, transient ischemic attack, or life-threatening arrhythmia within the prior 6 months 3. Uncontrolled atrial fibrillation/flutter at screening or other significant abnormality observed on electrocardiogram (ECG) 4. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure \> 90 mmHg. For subjects \> 60 years old and without diabetes mellitus, familial hypercholesterolemia, or cardiovascular disease: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure \> 90 mmHg 5. Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg 6. Use of oral contraceptive containing anti-androgens 7. Use of oral contraceptive containing 50 μg estrogen or more 8. Positive test result for Chlamydia or gonorrhea 9. Pregnancy or intention to become pregnant during this study (Note: A urine pregnancy test will be performed in all women prior to the administration of study medications.) 10. Lactating or delivery in the previous 6 months 11. Significant abnormal pap smear in the previous 12 months 12. History of bilateral oophorectomy 13. Other unexplained gynecological complaints, such as clinically relevant abnormal uterine bleeding patterns 14. Liver and/or renal insufficiency (aspartate aminotransferase and alanine aminotransferase \> 3 times the upper limit of normal and/or glomerular filtration rate \< 29 mL/min based on the Cockcroft and Gault formula) 15. Current clinically relevant endocrine disease or uncontrolled diabetes mellitus 16. Current clinically relevant neurological disease which, in the opinion of the investigator, would compromise the validity of study results, or which could form a contraindication for sildenafil and/or testosterone use 17. History of hormone-dependent malignancy 18. Vision impairment, such as partial or complete blindness or color blindness 19. Dyslexia 20. Positive test result for human immunodeficiency virus, hepatitis B, or hepatitis C (acute and chronic hepatitis infection) 21. History of (childhood) sexual abuse that, in the opinion of the investigator, could have negative psychological effects when testosterone is administered 22. (Treatment for) a psychiatric disorder that, in the opinion of the investigator, would compromise the validity of study results or which could be a contraindication for sildenafil and/or testosterone use 23. Current psychotherapeutic treatment for female sexual dysfunction 24. Current sexual disorder of vaginismus or dyspareunia according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (text revision). 25. A substance abuse disorder that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study (Mild or moderate alcohol consumption is allowed but must be stopped 12 hours before the home measurement \[Stroop task\].) 26. Positive test result for illicit drugs 27. Use of potent CYP3A4 inhibitors (eg, ritonavir, ketoconazole, itraconazole clarithromycin, erythromycin and saquinavir) 28. Use of potent CYP3A4 inducers (eg, carbamazepine, phenytoin, phenobarbital, St Johns wort, rifampin) 29. Use of nitrates or nitric oxide donor compounds 30. Use of selective serotonin reuptake inhibitors, tricyclic antidepressants, or other antidepressants 31. Use of any other medication that interferes with study medication (eg, monoamine oxidase \[MAO\] inhibitors \[includes classic MAO inhibitors and linezolid\]) 32. Use of medication (including herbs) that would compromise the validity of study results 33. Use of testosterone therapy within 6 months before study entry 34. Illiteracy, unwillingness, or inability to follow study procedures 35. Participation in other clinical trials within the last 30 days 36. Any other clinically significant abnormality or condition which, in the opinion of the investigator, might interfere with the participants ability to provide informed consent or comply with study instructions, compromise the validity of study results, or be a contraindication for sildenafil and/or testosterone use
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The number of satisfactory sexual encounters based on event questionnaires on active drug as compared to placebo during double-blind treatment period episodes in the domestic setting. | 20 weeks | Efficacy is estimated by self reporting by subjects using daily event questionnaires, recorded within 24 hours after a sexual event. The number of events between a 4-week baseline establishment period will be compared with the number of events during the 8 week double-blind treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sexual satisfaction | 20 Weeks | Sexual satisfaction will be evaluated based on a global satisfaction assessment comparing the 4-week establishment period with the 8 week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks. |
| Sexual desire and arousal | 20 Weeks | Sexual desire and arousal will be evaluated based on the 'desire' and 'arousal' domains of the Sexual Anamnesis Questionnaire, the Sexual Function questionnaire and weekly diaries throughout the course of the study. |
| Sexual motivation and inhibition | 20 Weeks | Sexual motivation and inhibition will be assessed using the Sexual Motivation Questionnaire and comparing sexual motivation and inhibition between the 4-week establishment period and the 8-week DB treatment period. In addition there is a 8 week run in period between the establishment period and the double blind treatment period for a total treatment period of 20 weeks. |
| Safety and toleration | 20 Weeks | Safety will be evaluated by: 1) AEs \[Number of patients reporting AEs, number of patients reporting drug related AEs\] 2)SAE \[Number of patients reporting SAEs, number of patients reporting drug related SAEs\]and 3) Changes in laboratory safety data \[Number of patients reporting abnormal lab safety data, number of patients reporting drug related abnormal lab safety data\]. These will be evaluated throughout the course of the study. |
Countries
United States
Outcome results
None listed